Hepatitis C - staying the course

A rash of failures for hepatitis C drugs, conflicting theories about the immune system's role and the looming issue of drug resistance make it impossible to predict when or how new therapies will make an impact. Ken Garber reports.

Published on Nature Biotechnology website. To read this in depth article click on the link on the right of the page